Navigation Links
Vion Pharmaceuticals Files for Chapter 11 Bankruptcy
Date:12/17/2009

NEW HAVEN, Conn., Dec. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), a pharmaceutical company focused on the development of novel cancer therapeutics, announced that it had voluntarily filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Vion is continuing to operate its business as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.

"We believe that the Chapter 11 process will allow us to maximize the value of the Company's assets and, if necessary, to conduct an orderly winding up or liquidation of the Company," said Alan Kessman, Chief Executive Officer. He added, "We believe that Onrigin(TM), Triapine® and our other preclinical assets should continue to be developed, if not by us then by others, as patients with cancer need additional treatment options as they face this devastating disease."

The bankruptcy filing became necessary as a result of the Company's need to conduct an additional randomized trial of its lead anticancer compound, Onrigin(TM) (laromustine) Injection, prior to approval for use in the United States. Earlier this week, the Company disclosed that it had received a complete response letter from the U.S. Food and Drug Administration ("FDA") relating to its New Drug Application for Onrigin(TM) filed in February 2009. In that letter, the FDA advised that the Company complete a randomized study or studies to define the efficacy and safety of Onrigin(TM) in the patient population proposed for the indication, and that the study or studies be designed to demonstrate a survival benefit that is clearly attributable to Onrigin(TM) with an acceptable safety profile in a well-characterized patient population.

The Company also announced that it had filed for a Special Protocol Assessment ("SPA") with the FDA related to a randomized
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... Huntington Memorial Hospital is the first facility ... valve replacement (TAVR), a minimally invasive replacement of heart ... to replace an aortic valve without a chest incision ... The procedure is performed by a dedicated Huntington ... Durairaj , MD, interventional cardiologist and Robbin Cohen ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... hip injuries is a growing field in orthopaedic medicine. ... with labral tear to confirm the pain etiology, research ... Medicine’s ( AOSSM ) Specialty Day suggests that pain ... outcomes following arthroscopic hip surgery. , “Our study ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... for patients with Type V AC joint injuries, according ... study, presented today at the American Orthopaedic Society for ... personnel returned to duty faster when surgery was not ... patients, with 7 receiving surgical treatment and 17 receiving ...
(Date:3/28/2015)... 2015 Andrew Hawley of Vintage Rock Posters ... concert posters. The Who and the Doors played together at ... 1968. According to Hawley, “The Who toured the United States ... college campuses. Perhaps the most famous Who poster was a ... the Doors on August 2, 1968 at the Singer Bowl ...
(Date:3/28/2015)... 28, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Physical Therapy Association Annual Conference to be held ... Hotel in Columbus, OH. , The OPTA ... exhibits with products and services. , Representatives ...
(Date:3/28/2015)... The "Petrick Sustainable Health System" ... After 18 years of research and experience with patients ... Dr. Jon Petrick is excited to be launching his ... the immediate benefits of this radical new system are ... strength of the immune system, faster healing of injuries, ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... -- Mayo Clinic has clarified the methods of diagnosis ... vessel disease of the brain and spinal cord that ... system vasculitis (PCNSV) can best be identified through a ... cerebral arteries), brain biopsy and other laboratory studies. , ...
... Inc. (Nasdaq: PMTI ), a leading developer of ... cosmetic treatments, will hold its,quarterly conference call of its ... at 11:30AM Eastern Time. If you would like to,participate, ... on that,day. The telephone replay will be available one ...
... the World,s First Accurate Non-Contact Clinical Thermometer, ... a division of,American Scientific Resources, (ASFX-OTC) today announced ... first non-contact clinical,thermometer in the world, now available ... 5-in-1, made in Italy and long,recommended by doctors ...
... no proof they help children under 6, and they may ... -- Beginning Thursday, a panel of experts at the U.S. ... over-the-counter cough and cold medicines for young children. , Such ... the FDA, who published a 365-page review on the issue ...
... a leading provider,of business intelligence solutions that combine ... announced this week that its,longstanding client, Miller Children,s ... children,s hospitals named to the 2007 Leapfrog Top ... its outstanding,performance," said Swati Abbott, President of MEDai. ...
... the evidence shows no link , THURSDAY, Oct. 18 (HealthDay ... stretching before or after exercise will not prevent muscle soreness, ... 10 studies, each involving from 10 to 30 people. , ... laboratory settings, and the time spent stretching by participants varied ...
Cached Medicine News:Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 2Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 3Health News:Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 2Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 4Health News:Leading Children's Hospital Utilizes MEDai's Solutions to Deliver Outstanding Care 2
... allows detection of SYBR Green I or ... range of fluorophores in the second channel ... for a multitude of applications such ... thermal cycler offers precision thermal control and ...
Inquire...
... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
Chemically Resistant Sealing Mat for 96ch, 1.1ml or 2.0ml, Deep Well, Round Available Sterile...
Medicine Products: